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Abstract (250 / 250 words) 25 
Nutrient sulfate has numerous roles in mammalian physiology and is essential for 26 
healthy fetal growth and development. The fetus has limited capacity to generate sulfate 27 
and relies on sulfate supplied from the maternal circulation via placental sulfate 28 
transporters. The placenta also has a high sulfate requirement for numerous molecular 29 
and cellular functions, including sulfate conjugation (sulfonation) to estrogen and 30 
thyroid hormone which leads to their inactivation. Accordingly, the ratio of sulfonated 31 
(inactive) to unconjugated (active) hormones modulates endocrine function in fetal, 32 
placental and maternal tissues. During pregnancy, there is a marked increase in the 33 
expression of genes involved in transport and generation of sulfate in the mouse 34 
placenta, in line with increasing fetal and placental demands for sulfate. The maternal 35 
circulation also provides a vital reservoir of sulfate for the placenta and fetus, with 36 
maternal circulating sulfate levels increasing by 2-fold from mid-gestation. However, 37 
despite evidence from animal studies showing the requirement of maternal sulfate 38 
supply for placental and fetal physiology, there are no routine clinical measurements of 39 
sulfate or consideration of dietary sulfate intake in pregnant women. This is also 40 
relevant to certain xenobiotics or pharmacological drugs which when taken by the 41 
mother use significant quantities of circulating sulfate for detoxification and clearance, 42 
and thereby have the potential to decrease sulfonation capacity in the placenta and fetus. 43 
This article will review the physiological adaptations of the placenta for maintaining 44 
sulfate homeostasis in the fetus and placenta, with a focus on pathophysiological 45 
outcomes in animal models of disturbed sulfate homeostasis. 46 
 47 
Key words: sulfate, sulfonation, placental adaptation, nutrient, 48 
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1. Introduction 49 
Sulfate is essential for numerous metabolic and cellular processes in mammalian 50 
physiology, particularly in placental and fetal tissues [1]. The conjugation of sulfate 51 
(sulfonation) to certain molecules, including thyroid hormone and steroids (e.g. 52 
estrogens) leads to their inactivation [2-4]. Furthermore, the sulfonated forms of steroids 53 
that are biosynthesized in the placenta, including estrogen sulfate and pregnenolone 54 
sulfate, are the major form of steroids transported into fetal circulation via ATP binding 55 
cassette (ABC) proteins, Na+-dependent organic anion transporter (SOAT) and the Na+-56 
independent organic anion transporting polypeptides (OATPs)  [3, 5]. Accordingly, the 57 
ratio of sulfonated (inactive and transportable across the syncytiotrophoblast cell 58 
membrane) to unconjugated (active) hormones has the potential to modulate endocrine 59 
function in fetal, placental and maternal physiology [3]. In addition, the sulfate content 60 
of proteoglycans, such as heparan sulfate and chondroitin sulfate, is important for 61 
sequestering growth factors (e.g. VEGF) which contributes to regulating tissue growth 62 
and development [6, 7]. Furthermore, the placenta and fetal liver express abundant 63 
levels of sulfotransferases that mediate the sulfonation of certain xenobiotics and 64 
pharmacological drugs that are potentially detrimental to fetal development [8, 9]. This 65 
is particularly important as the placenta and fetus have a limited capacity to detoxify 66 
xenobiotics via the glucuronidation pathway, and therefore rely on sulfonation as the 67 
major pathway for eliminating xenobiotics into the maternal circulation [10, 11]. 68 
Overall, sulfate biotransforms numerous endogenous and exogenous substrates in 69 
placental and fetal tissues (Fig. 1A). These numerous and diverse roles for sulfate 70 
during fetal development, require a sufficient supply of sulfate from maternal 71 
circulation, as well as adaptive responses of the placenta to meet the gestational needs 72 
of the developing fetus. This review highlights our current knowledge of maternal 73 
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sulfate supply to the placenta and fetus, and the placental adaptations to reduced sulfate 74 
availability from maternal circulation. 75 
2. Involvement of altered sulfate biology in fetal and placental pathologies.  76 
Over the past few decades, human and animal studies have linked several genes 77 
involved in sulfate biology with fetal and placental pathologies (Table 1). These genes 78 
encode proteins involved in five broad categories of sulfate biology: i) sulfate 79 
transporters that mediate the transfer of sulfate across the plasma membrane of cells, 80 
including the Na+-dependent sulfate cotransporters (SLC13A1 and SLC13A4) and Na+-81 
independent sulfate/anion exchangers in the SLC26 gene family [12, 13]; ii) 3’-82 
phosphoadenosine 5’-phosphosulfate (PAPS) synthetase which converts sulfate to 83 
the universal sulfonate donor, PAPS [14]; iii) sulfotransferases that mediate the 84 
intracellular sulfonation of endogenous substrates [15]; iv) sulfatases that remove 85 
sulfate from substrates [16]; and v) several ABC, SOAT and OATP proteins that are 86 
expressed in the placenta where they are proposed to transport sulfonated 87 
molecules such as steroids [3, 5, 17]. All of these steps in sulfate biology contribute 88 
to maintaining sulfate homeostasis in the placenta and fetus (Fig. 1B).   89 
More recently, studies in mice have shown the obligate requirement for maintaining 90 
high maternal circulating sulfate levels for a healthy pregnancy [18], as well as the 91 
severe and lethal consequences of blocking placental sulfate transfer to the fetus [19]. 92 
This is relevant when considering that certain xenobiotics, pharmacological drugs and 93 
physiological conditions can reduce maternal circulating sulfate levels [20-26]. In 94 
addition, dietary sulfate intake during pregnancy is not usually considered [27], despite 95 
evidence that diet can impact on circulating sulfate levels and sulfonation capacity [28-96 
30]. Collectively, numerous genetic, environmental and physiological conditions can 97 
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influence maternal circulating sulfate levels (Table 2), and potentially limit sulfate 98 
supply to the placenta and fetus. The physiological relevance of reduced sulfate levels in 99 
human pregnancy is unknown as sulfate is not routinely measured in clinical settings. 100 
However, with the recent development of a validated method for sulfate quantitation, as 101 
well as the establishment of maternal plasma sulfate reference ranges [31], interest in 102 
the clinical consequences of perturbed sulfate levels has expanded [32, 33].  103 
 104 
3. Sulfate is obtained from the diet and intermediary metabolism 105 
Sulfate is obtained from the diet as inorganic sulfate (SO42-) and from intermediary 106 
metabolism of sulfonated compounds and the sulfur-containing amino acids, methionine 107 
and cysteine [34, 35]. Approximately one third of average body sulfate requirements 108 
(0.2-1.5 g SO42- /day) are obtained from a well-balanced diet [36-39]. The sulfate 109 
content of foods ranges from high levels (>0.9 mg/g) in brassica vegetables and 110 
commercial breads to negligible levels (<0.1 mg/g) in fresh apples and oranges [38]. 111 
Drinking water also provides a source of sulfate, with levels exceeding 500 mg/L in 112 
spring water [36-38]. Sulfate in air contributes trace amounts of sulfate via inhalation 113 
(0.01-0.04 mg SO42- /day) for adults [40]. In addition, most prenatal multivitamin-114 
multimineral supplements contain sulfate (≈ 25-40 mg SO42- /tablet) in the form of 115 
cupric sulfate anhydrous, zinc sulfate and manganese sulfate. Animal studies have 116 
shown the nutritional value of sulfate in maintaining healthy growth [41] and the growth 117 
restriction consequences of sulfate deficiency, that can be reversed by sulfate 118 
supplementation [29, 30, 42, 43]. Overall, both food (≈ 0.85 g SO42- /day) and drinking 119 
water (≈ 0.78 g SO42- /day) contribute to the body’s sulfate requirements [39], 120 
particularly during pregnancy when fetal and placental sulfate demands are high. 121 
However, there is currently no recommended dietary intake for sulfate in humans, 122 
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because sulfate can be generated from the sulfur-containing amino acids, methionine 123 
and cysteine. Methionine is transsulfurated to cysteine, which can be catabolised to 124 
sulfate via a major pathway that involves cysteine dioxygenase (CDO), and via a minor 125 
pathway involving cystathionine γ–lyase (CTH) and cystathionine β–synthase (CBS) 126 
[44]. These pathways of intermediary metabolism account for almost all of cellular 127 
sulfate production, that is most abundant in the adult liver where sulfate requirements 128 
are high [1, 45]. The negligible levels of CTH and CDO in human and rodent fetal liver, 129 
suggests that the fetus may have limited capacity to generate its own sulfate [46, 47]. 130 
However, a more recent study showed increasing Cdo1 mRNA levels from E10.5 in the 131 
mouse fetus, with highest abundance in the embryo trunk, heart, nasal cavities and brain 132 
[48], suggesting that CDO1 may contribute to sulfate production in certain fetal tissues 133 
during development. Those findings have prompted further studies to investigate the 134 
relative contributions of sulfate from maternal circulation and the placenta, as well as 135 
the developmental consequences of blocking maternal sulfate supply to the fetus [18, 136 
19, 31]. 137 
4. Sulfate is an obligate nutrient supplied from mother to fetus 138 
Sulfate is the fourth most abundant anion in human plasma, with levels maintained at 139 
approximately 300 µmol/L in adult males and non-pregnant females. During human and 140 
animal gestation, maternal circulating sulfate levels increase by approximately 2-fold, 141 
which is proposed to be an adaptive physiological response to meet the gestational 142 
needs of the growing fetus [18, 31]. In pregnant women, this increase is remarkable and 143 
indicates active up-regulation of sulfate levels, as most circulating analytes usually 144 
decrease slightly in pregnancy due to changes in extracellular fluid volume and renal 145 
function [49, 50]. The inverse correlation of increased plasma sulfate levels with 146 
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decreased urinary sulfate excretion, suggests enhanced renal reabsorption is responsible 147 
for maintaining high sulfataemia in pregnancy. 148 
Sulfate reabsorption occurs in the renal proximal tubule, and is mediated by the 149 
SLC13A1 and SLC26A1 sulfate transporters [51]. SLC13A1 is a sodium-dependent 150 
sulfate transporter, which can also transport other tetraoxyanions (i.e. selenate, 151 
molybdate, tungstate and thiosulfate) [52], suggesting these compounds may potentially 152 
inhibit sulfate transport. SLC26A1 exchanges sulfate with structurally similar anions, 153 
inlcuding oxalte, bicarbonate and chloride [53]. In the kidney, SLC13A1 mediates the 154 
first step of sulfate reabsorption across the apical membrane of epithelial cells in the 155 
proximal tubule [54], and SLC26A1 mediates the second step across the basolateral 156 
membrane [55] (Fig. 1B). In mouse pregnancy, both Slc13a1 and Slc26a1 mRNA 157 
expression in the kidney increases from early gestation (E4.5), which correlates with 158 
increased plasma sulfate level [18, 56]. Targeted distruption of the Slc13a1 or Slc26a1 159 
genes in mice leads to urinary sulfate wasting and hyposulfataemia [57, 58], 160 
demonstrating the essential role of these genes in maintaining circulating sulfate levels. 161 
During pregnany, Slc13a1 null mice remain hyposulfataemic, which leads to fetal 162 
hyposulfataemia and late gestational misscarriage [18]. These findings are relevant 163 
when considering genetic variants in human SLC13A1 and SLC26A1, that are associated 164 
with reduced plasma sulfate level and decreased sulfonation capacity [21, 32, 33, 59] 165 
but their involvement with altered sulfate status in pregnancy has not been determined. 166 
Together, these human and animal studies indicate the importance of maintaining high 167 
circulating sulfate levels in pregnancy, which warrants further studies to determine the 168 
clinical relevance of SLC13A1 and SLC26A1 in human gestation. 169 
Early studies showed the expression of the SLC13A4 sodium-sulfate co-transporter in 170 
human and mouse placenta where it was proposed to be mediating transfer of sulfate 171 
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from maternal circulation to the fetus [60, 61]. More recently, abundant levels of human 172 
SLC13A4 and mouse Slc13a4 mRNA were localised to the syncytiotrophoblast layer of 173 
the placenta, the site of maternal-fetal nutrient exchange [56, 62]. While no evidence of 174 
sodium-dependent sulfate transport has yet been demonstrated in isolated human 175 
syncytiotrophoblast vesicles [63], targeted deletion of Slc13a4 in mice did impair 176 
sulfate transfer in mid-gestion and led to severe fetal developmental abnormalities and 177 
late gestational fetal death [64]. Those findings demonstrate the obligate requirement of 178 
sulfate, as well as the vital role of placental Slc13a4 for healthy fetal growth and 179 
development.  180 
5. Placental adaptations to fetal sulfate demands and maternal sulfate supply  181 
During mouse pregnancy, placental Slc13a4, Slc26a2, and Slc26a7 mRNA expression 182 
increases within the labyrinth region from mid-gestation (≈ E10.5) [56], when 183 
chorioallantoic exchange is established [65]. Slc13a4 and Slc26a2 are the most 184 
abundant sulfate transporters expressed by the syncytiotrophoblast layers; Slc13a4 is 185 
expressed by the second layer of syncytiotrophoblast (SynT-II) closest to the fetal 186 
endothelial cells, and Slc26a2 is expressed by the first layer of syncytiotrophoblast 187 
(SynT-I) adjacent to the maternal circulation [56]. Due to this differential expression 188 
pattern, the deletion of Slc13a4 was hypothesised to impair sulfate transfer from the 189 
maternal to the fetal circulation without affecting sulfate uptake by the placenta itself.    190 
Indeed, deletion of Slc13a4 resulted in severe developmental defects in Slc13a4 null 191 
fetuses that increase in severity as gestation progresses, but overall placental 192 
development appeared normal [19] (Fig. 1C). The most striking features of Slc13a4 null 193 
embryos in late gestation include pale skin, subcutaneous oedema, craniofacial 194 
malformations, vascular haemorrhaging and skeletal defects, highlighting the 195 
detrimental consequences of sulfate deficiency on multiple organ systems. A 196 
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hypomorphic allele of Slc26a2 has also been shown to disrupt skeletogenesis in mice 197 
[66], but the effects of this mutation on placental development or transplacental sulfate 198 
transport have not been explored. It is possible that deletion of Slc26a2 from the first 199 
syncytial layer will not only impair maternal to fetal placental sulfate transport as in 200 
Slc13a4 null placentas, but also disrupt sulfate availability for placental functions as 201 
well, and potentially have even more severe phenotypes. Earlier studies detected 202 
SLC26A2 mRNA and protein in placental villi [67]. More recently, SLC26A2 mRNA 203 
was localised to cytotrophoblast cells of human term placentae [62]. Whilst its 204 
physiological role in human placenta is unknown, SLC26A2 mRNA levels were 205 
reported to be more abundant in cytotrophoblasts of term male babies when compared 206 
to female babies [62], suggesting a potential higher requirement for sulfate usage (i.e. 207 
estrogen and/or thyroid hormone sulfonation) in the placenta of male babies. These 208 
potential sex differences in placental SLC26A2 expression may be relevant to the lower 209 
venous cord plasma sulfate levels in male babies when compared to female babies [31], 210 
which warrants further studies of placental SLC26A2 and endocrine status. Overall, 211 
sulfate transport capacity increases from mid-gestation in mice, and the homologous 212 
genes in human placenta (SLC13A4, SLC26A2 and SLC26A1) are abundantly expressed 213 
in analogous placental cell types, suggesting a conserved physiological role for these 214 
genes and sulfate usage across species. 215 
Whilst the maternal circulation provides an important source of sulfate for the placenta 216 
and fetus, it is unclear whether the placenta generates sulfate. The major pathway of 217 
sulfate generation from cysteine requires cysteine dioxygenase, which is expressed in 218 
the maternal decidua of the mouse placenta [48]. The increasing Cdo1 mRNA levels in 219 
mouse placenta from E10.5, suggests a role for Cdo1 in decidual function in late 220 
gestation. This is most likely relevant when considering the increasing sulfate 221 
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requirements of the decidua for estrogen and thyroid hormone sulfonation in mouse 222 
(from E12.5) and human (third trimester) gestation [68-70]. These proposed roles for 223 
CDO1 in the maternal decidua are also supported by a Cdo1 knock-out mouse study 224 
[44]; mating Cdo1 heterozygous male and female mice produced the Mendelian 225 
distribution of Cdo1+/+, Cdo1+/- and Cdo1-/- genotypes that all survived at birth (in these 226 
crosses the decidua is Cdo1+/-), whereas Cdo1 null females mated with Cdo1 wildtype 227 
males, carry Cdo1+/- fetuses to term that do not survive (in these crosses the decidua is 228 
Cdo1-/-). These findings indicate an essential role for CDO1 in maintaining sulfate 229 
homeostasis in the decidua. However, it would appear that CDO1 is not sufficient to 230 
meet all placental requirements for sulfate because maternal hyposulfataemia in the 231 
Slc13al null mouse leads to placental phenotypes and fetal loss [18, 57]. 232 
Circulating sulfate levels in the Slc13a1 null mouse (≈ 0.2mmol/L) is reduced by 233 
approximately 80% when compared to wildtype mice (≈ 1.0mmol/L) [57]. Slc13a1 null 234 
mice remain hyposulfataemic throughout pregnancy, which leads to fetal loss in late 235 
gestation (E12.5 to E18.5) as well as changes to the placental architecture from E12.5, 236 
including enlarged labyrinth and spongiotrophoblast layers [18]. The enlarged 237 
spongiotrophoblast layer in Slc13a1 null mice, has also been noted in other mouse 238 
models of reduced fetal survival, including trisomy 15 syndrome [71], hydroxysteroid 239 
17β dehydrogenase 2 knockout mice [72], and over-expression of epidermal growth 240 
factor receptor [73]. These findings suggesting a common physiological response such 241 
as the endocrine activity of spongiotrophoblasts [74], which is essential for the 242 
maintenance of pregnancy and fetal development [75-77]. Interestingly, 243 
hyposulfataemia in pregnant Slc13a1 null mice, did not lead to any changes in placental 244 
mRNA expression levels of the Slc13a4 and Slc26a2 sulfate transporters, as well as 2 245 
sulfotransferases Sult1e1 and Hs3st1 that contribute vital roles in sulfonation of 246 
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estrogen and heparan sulfate, respectively [70, 78].  Those findings suggest that the 247 
Slc13a4, Slc26a2, Sult1e1 and Hs3st1 genes in the placenta are not sensitive to low 248 
maternal circulating sulfate levels. In addition, Slc26a1 is expressed by 249 
spongiotrophoblast of the mouse placenta, however, the effects of genetic deletion on 250 
placental development or function have not been investigated [56]. 251 
Taken together, the above mentioned mouse studies have shown the importance of 252 
sulfate biology-related genes in the placenta, which are required for mediating sulfate 253 
supply to the fetus, as well as maintaining sulfate homeostasis within the placenta. In 254 
particular, the placental phenotypes of pregnant Slc13a1 and Cdo1 null mice suggest 255 
that reduced sulfate availability in the placenta most likely perturbs endocrine function, 256 
which then leads to placental dysfunction and subsequent fetal loss. These placental 257 
phenotypes in the hyposulfataemic pregnant Slc13a1 null mice were not observed in the 258 
normo-sulfataemic pregnant Slc13a4 null mice, despite both models leading to fetal 259 
sulfate deficiency (Fig. 1C). This observation suggests that the placental phenotype in 260 
Slc13a1 null mice is unlikely to be a result of altered fetal sulfate homeostasis (i.e. fetal 261 
endocrine status) but rather reduced maternal sulfate supply to the placenta, which 262 
supports the proposed impact of decreased sulfonation capacity on placental endocrine 263 
function. 264 
 265 
6. Summary 266 
The numerous roles of sulfate in placental and fetal physiology, together with the 267 
impact of disturbed sulfate homeostasis on pregnancy outcomes in animal models, 268 
cannot be underestimated. The conserved role of sulfate transporters, PAPS synthetase, 269 
sulfotransferases and sulfatases across species, is a testament to the importance of 270 
sulfate in physiological functions, and warrants further studies to determine the clinical 271 
relevance of maternal hyposulfataemia and fetal sulfate deficiency. In particular, the 272 
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past few decades of research have shown significant sulfate-related pathologies in 273 
animal models but many of these genes and dietary/environmental conditions have yet 274 
to be linked to human health. Increasing our knowledge of how maternal blood sulfate 275 
levels are regulated, as well as the placenta adaptions to high and low sulfate 276 
availability, opens up the possibility for providing dietary and medication advice, as 277 
well as genetic counselling to pregnant women. In summary, this review has highlighted 278 
the importance of sulfate supply to the fetus via the placenta, and the adaptive response 279 
of the placenta to fetal sulfate demands and maternal sulfate supply. This information 280 
provides a reference for directing future studies of placental sulfate biology which is 281 
relevant to maternal and child health outcomes. 282 
  283 
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Figure Legend 296 
 297 
Fig. 1. Physiological roles and regulation of sulfate in pregnancy. A) Sulfate 298 
contributes to numerous biochemical and cellular processes. B) Maternal, placental and 299 
fetal contributions to maintaining sulfate homeostatsis. Disruption of pathways that 300 
mediate sulfate transport (step 1, renal reabsorption; step 2, placental sulfate transport 301 
from mother to fetus; step 3, sulfate transport across the plasma membrane of placental 302 
and fetal cells for maintaining intracellular sulfate level), or intracellular generation of 303 
PAPS or sulfonation of substrates (steps 4-5) can lead to placental and fetal pathologies 304 
(as shown in Table 1). C) In mice: (a) high maternal and fetal circulating sulfate level 305 
are required for maintaining healthy placental and fetal phenotypes; (b) low maternal 306 
circulating sulfate level in pregnancy leads to low fetal circulating sulfate level, as well 307 
as placental phenotypes and fetal loss [18]; (c) despite high maternal circulating level, 308 
the loss of placental SLC13A4 sulfate transporter leads to negligible fetal sulfate level 309 
and severe/lethal fetal phenotypes but no apparent phenotypes in the placenta  [19]. 310 
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Table 1 545 
Placental and fetal pathologies linked to genes involved in sulfate biology 546 
Sulfate transporters 547 
 548 
PAPS transporter 549 
 550 
Sulfotransferases 551 
 552 
Sulfatases 553 
Gene Species Condition Reference 
Slc13a1 Mouse Hyposulfataemia, late gestational fetal loss, increased 
placental labyrinth and spongiotrophoblast layers. 
[18, 57] 
Slc13a4  Mouse Fetal abnormalities, including skeletal defects, vascular 
haemorrhaging, craniofacial malformations and 
embryonic death 
[19] 
SLC26A2 Human Skeletal dysplasias [12] 
Slc26a2 Mouse Growth retardation, skeletal dysplasia [66] 
PAPSS2 Human Brachyolmia, mild epiphyseal and metaphyseal changes [79] 
Papss2 Mouse Brachymorphic, shortened limbs, dome shaped skull [79] 
Sult1e1 Mouse Placental thrombosis and spontaneous fetal loss. [70] 
Hs2st Mouse Eye and skeletal defects, kidney agenesis, neonatal 
death 
[80] 
Hs3t1 Mouse Reduced fecundity delayed placental development,  
intrauterine growth retardation 
[78, 81] 
Hs6st1 Mouse Reduced fecundity, perturbed placental development [82] 
Tpst1 Mouse Fetal loss and reduced body weight [83] 
Tpst2 Mouse Fetal growth retardation and hypothyroidism [84] 
ARSE Human Chondrodysplasia punctata 1 (X-linked recessive) [85] 
SULF1 Human Mesomelia-synostoses syndrome [86] 
Sulf1 Mouse Developmental defects, neonatal lethality [87] 
Sulf2 Mouse Developmental defects, neonatal lethality [87] 
SUMF1 Human Congenital growth retardation, skeletal abnormalities, 
neurological defects and early mortality 
[88] 
Sumf1 Mouse Congenital growth retardation, skeletal abnormalities, 
neurological defects and early mortality 
[89] 
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Table 2 554 
Conditions involved with regulating circulating sulfate level 555 
Genetic 556 
Environmental 557 
 558 
Physiological 559 
 560 
Factor Species Role Reference 
Slc13a1 Human, Mouse, 
Dog, Sheep 
Intestinal absorption and renal reabsorption of 
sulfate. Loss leads to renal sulfate wasting and 
hyposulfataemia. 
[32, 33, 57, 
90, 91] 
Slc26a1 Mouse Intestinal absorption and renal reabsorption of 
sulfate. Loss leads to renal sulfate wasting and 
hyposulfataemia. 
[58] 
Diet Human, Rat High and low sulfate diets correlate to plasma 
sulfate level. 
[28-30] 
NSAIDs Rat Decreases renal reabsorption of sulfate. [24] 
Glucocorticoids Rat Decreases renal reabsorption of sulfate leading to 
renal sulfate wasting. 
[24] 
Acetaminophen Human, Mouse Depletion of circulating plasma sulfate level. [21, 22] 
Pregnancy Human, Mouse Increased renal reabsorption of sulfate and leads 
to 2-fold increase in plasma sulfate level. 
[18, 31] 
Metabolic acidosis Rat Decreases renal reabsorption of sulfate. [23] 
Hypokalaemia Rat Decreases renal reabsorption of sulfate. [23] 
Growth Hormone Rat Increases renal reabsorption of sulfate. [25] 
Hypothyroidism Rat Decreases renal reabsorption of sulfate. [26] 
Vitamin D 
deficiency 
Rat Decreases renal reabsorption of sulfate leading to 
decreased plasma sulfate level. 
[20] 
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